Tag: biomedical
-
Synthetic Antibody Company Goes Public in $230M Merger
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger.
-
Elephant Genetic Codes to be Sequenced, Preserved
A biotechnology company using gene editing to preserve animal species is sequencing the genomes of three elephant varieties to help prevent their extinction.
-
Foundation Plans $1B for Longevity Research
A charitable foundation began work today supporting research on human longevity, with the goal of increasing lifespans to more than 120 years.
-
Genomic Analysis Shown to Detect Early Pancreatic Cancer
Analysis of genomic and protein indicators in blood samples is shown to detect pancreatic cancer in earlier stages, increasing chances of survival.
-
Trial Begins Testing RNA Therapy for Alcohol Disorder
A clinical trial is underway testing a therapy that silences genes to create reactions in people with alcohol use disorder to help them stop drinking.
-
Covid-19 Nasal Spray Vaccine Trial Underway
A clinical trial testing the safety of a Covid-19 vaccine from an engineered virus found in dogs and given as a nasal spray enrolled its first participant.
-
Off-the-Shelf Stem Cell Company Forms, Gains $72M
A new enterprise developing packaged blood-forming stem cells as therapies for a range of diseases began operations and raised $72 million in venture funds.
-
Gene Therapy Delivery Company Gains $26M in Early Funds
A developer of delivery methods for gene therapies promising greater safety for patients is raising $26 million in its first venture funding round.
-
Trial Underway Testing Cancer Drug as Covid-19 Therapy
A clinical trial enrolled and dosed its first participant testing an oral drug, initially designed to treat cancer, as a therapy for mild Covid-19 infections.
-
Animal Genome Biotech Raises $9M in Seed Funds
A company discovering new drugs for a range of diseases based on the genomes of hibernating animals is raising $9 million in seed funds.